ESA JANTUNEN

Contact info

Publications

• Intke, C; Korpelainen, S; Lappalainen, M; Vänskä, M; Hämäläinen, S; Pulkki, K; Jantunen, E; Juutilainen, A; Purhonen, AK. 2021. Serum caspase-cleaved cytokeratin-18 fragment as a prognostic biomarker in hematological patients with febrile neutropenia Clinical and experimental medicine 2022; 22 1: 83-93. 2021
• Partanen, Anu; Kuittinen, Outi; Turunen, Antti; Valtola, Jaakko; Pyörälä, Marja; Kuitunen, Hanne; Vasala, Kaija; Kuittinen, Taru; Mäntymaa, Pentti; Pelkonen, Jukka; Jantunen, Esa; Varmavuo, Ville. 2021. Blood Graft and Outcome After Autologous Stem Cell Transplantation in Patients With Primary Central Nervous System Lymphoma Journal of Hematology 10 6: 246-254. 2021
• Partanen, Anu; Turunen, Antti; Silvennoinen, Raija; Pyörälä, Marja; Valtola, Jaakko; Siitonen, Timo; Putkonen, Mervi; Sankelo, Marja; Sikiö, Anu; Penttilä, Karri; Kuittinen, Taru; Pelkonen, Jukka; Mäntymaa, Pentti; Jantunen, Esa; Varmavuo, Ville. 2021. Comparison of CD34 + cell mobilization, blood graft cellular composition, and post-transplant outcome in myeloma patients mobilized with filgrastim or pegfilgrastim added to low-dose cyclophosphamide: A prospective multicenter study Transfusion 61 11: 3202-3212. 2021
• Rajamäki, Aino; Sunela, Kaisa; Prusila, Roosa EI; Kuusisto, Milla EL; Mercadal, Santiago; Selander, Tuomas; Kuitunen, Hanne; Pollari, Marjukka; Jantunen, Esa; Nystrand, Ilja; Sancho, Juan-Manuel; Sorigue, Marc; Kuittinen, Outi. 2021. Female patients with follicular lymphoma have a better prognosis if primary remission lasts over 24 months Leukemia & lymphoma 62 7: 1639-1647. 2021
• Turunen, A; Silvennoinen, R; Partanen, A; Valtola, J; Siitonen, T; Putkonen, M; Sankelo, M; Pyörälä, M; Kuittinen, T; Penttilä, K; Sikiö, A; Savolainen, ER; Mäntymaa, P; Pelkonen, J; Varmavuo,V; Jantunen, E. 2021. Autograft cellular composition and outcome in myeloma patients: Results of the prospective multicenter GOA study Transfusion 61 6: 1830-1844. 2021
• Lawless, Sarah; Sbianchi, Giulia; Morris, Curly; Iacobelli, Simona; Bosman, Paul; Blaise, Didier; Reményi, Péter; Byrne, J.L.; Mayer, Jiri; Apperley, Jane; Lund, Johan; Kobbe, Guido; Schaap, Nicolaas; Isaksson, Cecilia; Lenhoff, Stig; Basak, Grzegorz; Touzeau, Cyrille; Wilson, Keith M.O.; González Muñiz, Soledad; Scheid, Christof et al. [incl. Jantunen, Esa]. 2021. IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study Clinical lymphoma myeloma and leukemia 21 10: 686-693. 2021
• Partanen, Anu; Turunen, Antti; Valtola, Jaakko; Vasala, Kaija; Ågren, Lasse; Penttilä, Karri; Pyörälä, Marja; Kuittinen, Taru; Mäntymaa, Pentti; Pelkonen, Jukka; Jantunen, Esa; Varmavuo, Ville. 2020. A prospective comparison of pegfilgrastim and lipegfilgrastim combined with chemotherapy in the mobilization of CD34+ cells in NHL patients Journal of clinical apheresis 35 4: 255-263. 2020
• Uotila, PM; Lemma, SA; Haapasaari, KM; Porvari, K; Skarp, S; Soini, Y; Jantunen, E; Turpeenniemi-Hujanen, T; Kuittinen, O. 2020. Prognostic significance of Twist, ZEB1 and Slug in peripheral T-cell lymphomas Hematology 25 1: 241-246. 2020
• Turunen, Antti; Valtola, Jaakko; Partanen, Anu; Ropponen, Antti; Kuittinen, Outi; Kuitunen, Hanne; Vasala, Kaija; Ågren, Lasse; Penttilä, Karri; Keskinen, Leena; Savolainen, Eeva-Riitta; Pyörälä, Marja; Kuittinen, Taru; Selander, Tuomas; Mäntymaa, Pentti; Pelkonen, Jukka; Jantunen, Esa; Varmavuo, Ville. 2020. Autograft cellular composition and outcome in NHL patients: results of the prospective multicenter GOA study Leukemia & lymphoma 61 9: 2082-2092. 2020
• Turunen, Antti; Partanen, Anu; Valtola, Jaakko; Ropponen, Antti; Siitonen, Timo; Kuittinen, Outi; Kuitunen, Hanne; Putkonen, Mervi; Sankelo, Marja; Keskinen, Leena; Savolainen, Eeva-Riitta; Pyörälä, Marja; Kuittinen, Taru; Silvennoinen, Raija; Penttilä, Karri; Sikiö, Anu; Vasala, Kaija; Mäntymaa, Pentti; Pelkonen, Jukka; Varmavuo, Ville; et al.. 2020. CD34+ cell mobilization, blood graft composition, and posttransplant recovery in myeloma patients compared to non-Hodgkin's lymphoma patients: results of the prospective multicenter Goa study Transfusion 60 7: 1519-1528. 2020
• Partanen, A; Turunen, A; Valtola, J; Pyörälä, M; Vasala, K; Kuittinen, O; Kuitunen, H; Penttilä, K; Kuittinen, T; Mäntymaa, P; Pelkonen, J; Varmavuo, V Jantunen, E. 2020. Autologous stem cell transplantation in peripheral T-cell lymphoma: better mobilization of blood CD34 + cells is associated with improved survival Leukemia & lymphoma 61 12: 3027-3029. 2020
• Partanen, Anu; Turunen, Antti; Valtola, Jaakko; Pyörälä, Marja; Vasala, Kaija; Kuittinen, Outi; Kuitunen, Hanne; Penttilä, Karri; Keskinen, Leena; Kuittinen, Taru; Mäntymaa, Pentti; Pelkonen, Jukka; Varmavuo, Ville; Jantunen, Esa. 2020. Mobilization characteristics, blood graft composition, and outcome in diffuse large B-cell lymphoma after autologous stem cell transplantation: Results from the prospective multicenter GOA study Transfusion 2021; 61 2: 516-525. 2020
• Lappalainen, Marika; Hämäläinen, Sari; Romppanen, Tuomo; Pulkki, Kari; Pyörälä, Marja; Koivula, Irma; Jantunen, Esa; Juutilainen, Auni. 2020. Febrile neutropenia in patients with acute myeloid leukemia: outcome in relation to qSOFA score, C-reactive protein and blood culture findings European journal of haematology 105 6: 731-740. 2020
• Kuitunen, H; Kaprio, E; Karihtala, P; Makkonen, V; Kauppila, S; Haapasaari, KM; Kuusisto, M; Jantunen, E; Turpeenniemi-Hujanen, T; Kuittinen, O. 2020. Impact of central nervous system (CNS) prophylaxis on the incidence of CNS relapse in patients with high-risk diffuse large B cell/follicular grade 3B lymphoma Annals of hematology 99 8: 1823-1831. 2020
• Korpelainen, Sini; Hämäläinen, Sari; Vänskä, Matti; Koivula, Irma; Pulkki, Kari; Jantunen, Esa; Juutilainen, Auni; Purhonen, Anna-Kaisa. 2020. Plasma level of interleukin-18 and complicated course of febrile neutropenia in hematological patients after intensive chemotherapy Cytokine 129: 155021. 2020
• Jantunen, Esa; Valtola, Jaakko; Partanen, Anu; Turunen, Antti; Kuittinen, Taru; Silvennoinen, Raija; Pyörälä, Marja; Mäntymaa, Pentti; Pelkonen, Jukka; Varmavuo, Ville. 2020. Pleriksafori kantasolujen mobilisaatiossa autologista siirtoa varten Duodecim 136 9: 997-1004. 2020
• Luoma, S; Anttila, P; Säily, M; Lundan, T; Heiskanen, J; Siitonen, T; Kakko, S; Putkonen, M; Ollikainen, H; Terävä, V; Sankelo, M; Partanen, A; Launonen, K; Räsänen, A; Sikiö, A; Suominen, M; Bazia, P; Kananen, K; Lievonen, J; Selander, T; et al. [incl. Mäntymaa, P; Jantunen, E]. 2019. RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group Annals of hematology 98 12: 2781-2792. 2019
• Säily, Marjaana; Silvennoinen, Raija; Jantunen, Esa; Anttila, Pekka; Lievonen, Juha; Putkonen, Mervi. 2019. Monimuotoinen myelooma Duodecim 135 12: 1171-1179. 2019
• Sorigue, M; Prusila, REI; Jauhiainen, J; Mercadal, S; Postila, A; Salmi, P; Tanhua, T; Tikkanen, S; Kakko, S; Kuitunen, H; Pollari, M; Nystrand, I; Kuusisto, MEL; Vasala, K; Jantunen, E; Korkeila, E; Karihtala, P; Sancho, JM; Turpeenniemi-Hujanen, T; Kuittinen, O. 2019. Incidence of solid cancer in patients with follicular lymphoma Acta oncologica 58 11: 1564-1569. 2019
• Prusila, REI; Sorigue, M; Jauhiainen, J; Mercadal, S; Postila, A; Salmi, P; Tanhua, T; Tikkanen, S; Kakko, S; Kuitunen, H; Pollari, M; Nystrand, I; Kuusisto, MEL; Vasala, K; Jantunen, E; Korkeila, E; Karihtala, P; Sancho, JM; Turpeenniemi-Hujanen, T; Kuittinen, O. 2019. Risk of secondary haematological malignancies in patients with follicular lymphoma: an analysis of 1028 patients treated in the rituximab era British journal of haematology 187 3: 364-371. 2019
• Sureda, A; Chabannon, C; Masszi, T; Pohlreich, D; Scheid, C; Thieblemont, C; Wahlin, BE; Sakellari, I; Russell, N; Janikova, A; Dabrowska-Iwanicka, A; Touzeau, C; Esquirol, A; Jantunen, E; van der Werf, S; Bosman, P; Boumendil, A; Liu, Q; Celanovic, M; Montoto, S; et al.. 2019. Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor Bone marrow transplantation 2020; 55: 613-622. 2019
• Kari, E; Teppo, HR; Haapasaari, KM; Kuusisto, MEL; Lemma, A; Karihtala, P; Pirinen, R; Soini, Y; Jantunen, E; Turpeenniemi-Hujanen, T; Kuittinen, O. 2019. Nuclear factor erythroid 2-related factors 1 and 2 are able to define the worst prognosis group among high-risk diffuse large B cell lymphomas treated with R-CHOEP Journal of clinical pathology 72 4: 316-321. 2019
• González-Barca; E; Boumendil, A; Blaise, D; Trnený, M; Masszi, T; Finel, H; Michieli, MG; Bittenbring, JT; Gritti, G; Snowden, JA; Bishton, M; Bruno, B; de Villambrosia, SG; Janikova, A; Leleu, X; Anagnostopoulos, A; Poiré, X; Crysandt, M; Özkurt, ZN; Vandenberghe, E; et al. [incl. Jantunen, E]. 2019. Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy: A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT) Bone marrow transplantation 2020; 55: 393-399. 2019
• Alexander, T; Samuelson, C; Daikeler, T; Henes, J; Akil, M; Skagerlind, L; Ehninger, G; Jantunen, E; Badoglio, M; Farge, D; Snowden, JA; on behalf of the BMT Autoimmune Diseases Working Party. 2019. Autologous haematopoietic stem cell transplantation (HSCT) for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: a retrospective survey of patients reported to European Society for Blood and Marrow Transplantation (EBMT) registry Bone marrow transplantation [Published 17 December 2019]: 1-4. 2019
• Becker, S; Korpelainen, S; Arvonen, M; Hämäläinen, S; Jantunen, E; Lappalainen, M; Pulkki, K; Riikonen, P; Juutilainen, A. 2019. MMP-10 and TIMP-1 as indicators of severe sepsis in adult hematological patients with febrile neutropenia Leukemia & lymphoma 60 12: 3036-3043. 2019
• Jantunen, Esa; Varmavuo, Ville; Pelkonen, Jukka; Valtola, Jaakko. 2019. Importance of early immune recovery after autologous hematopoietic cell transplantation in lymphoma patients Leukemia & lymphoma 60 9: 2115-2121. 2019
• Auner, Holger W; Iacobelli, Simona; Sbianchi, Giulia; Knol-Bout, Cora; Blaise, Didier; Russell, Nigel H; Apperley, Jane F; Pohlreich, David; Browne, Paul V; Kobbe, Guido; Isaksson, Cecilia; Lenhoff, Stig; Scheid, Christof; Touzeau, Cyrille; Jantunen, Esa; Anagnostopoulos, Achilles; Yakoub-Agha, Ibrahim; Tanase, Alina; Schaap, Nicolaas; Wiktor-Jedrzejczak, Wieslaw; et al.. 2018. Melphalan 140 mg/m2 or 200 mg/m2 for autologous trasnplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party HAEMATOLOGICA 103 3: 514-521. 2018
• Intke, Carina; Korpelainen, Sini; Hämäläinen, Sari; Vänskä, Matti; Koivula, Irma; Jantunen, Esa; Pulkki, Kari; Juutilainen, Auni. 2018. Interleukin-1 receptor antagonist as a biomarker of sepsis in neutropenic haematological patients EUROPEAN JOURNAL OF HAEMATOLOGY 101 5: 691-698. 2018
• Lappalainen, Marika; Jokkala, Jenna; Juutilainen, Auni; Hämäläinen, Sari; Koivula, Irma; Jantunen, Esa; Hanhineva, Kati; Pulkki, Kari. 2018. Novel Biomarker Candidates for Febrile Neutropenia in Hematological Patients Using Nontargeted Metabolomics Disease markers 2018: 6964529. 2018
• Partanen, A; Valtola, J; Ropponen, A; Kuitunen, H; Kuittinen, O; Vasala, K; Ågren, L; Penttilä, K; Keskinen, L; Pyörälä, M; Nousiainen, T; Selander, T; Mäntymaa, P; Pelkonen, J; Varmavuo, V; Jantunen, E. 2018. Comparison of filgrastim, pegfilgrastim, and lipegfilgrastim added to chemotherapy for mobilization of CD34+ cells in non-Hodgkin lymphoma patients Transfusion 2019; 59 1: 325-334. 2018
• Peroja, P; Pedersen, M; Mantere, T; Nørgaard, P; Peltonen, J; Haapasaari, KM; Böhm, J; Jantunen, E; Turpeenniemi-Hujanen, T; Rapakko, K; Karihtala, P; Soini, Y; Vasala, K; Kuittinen, O. 2018. Mutation of TP53, translocation analysis and immunohistochemical expression of MYC, BCL-2 and BCL-6 in patients with DLBCL treated with R-CHOP Scientific Reports 8 1: 14814. 2018
• Prusila, Roosa; Peroja, Pekka; Jantunen, Esa; Turpeenniemi-Hujanen, Taina; Kuittinen Outi. 2018. Treatment of Diffuse Large B-cell Lymphoma in Elderly Patients: Replacing Doxorubicin with either Epirubicin or Etoposide (VP-16) Hematological oncology 2019; 37 2: 136-142. 2018
• Rönkkö, Rosa; Juutilainen, Auni; Koivula, Irma; Vänskä, Matti; Nousiainen, Tapio; Jantunen, Esa; Hämäläinen, Sari. 2018. Changes in the microbiological epidemiology of febrile neutropenia in autologous stem cell transplant recipients Infectious diseases 50 6: 436-442. 2018
• Valtola, J; Silvennoinen, R; Ropponen, A; Siitonen, T; Säily, M; Sankelo, M; Putkonen, M; Partanen, A; Pyörälä, M; Savolainen, ER; Mäntymaa, P; Pelkonen, J; Jantunen, E; Varmavuo, V. 2018. Blood graft composition and post-transplant recovery in myeloma patients mobilized with plerixafor: a prospective multicenter study Leukemia & lymphoma 2019; 60 2: 453-461. 2018
• Lappalainen Marika, Hämäläinen Sari, Juutilainen Auni, Koivula Irma, Pulkki Kari, Jantunen Esa. 2017. Asymmetric dimethylarginine in the assessment of febrile neutropenia in hematological patients. SCANDINAVIAN JOURNAL OF CLINICAL AND LABORATORY INVESTIGATION 77 2: 130-134. 2017
• Purhonen Anna-Kaisa, Juutilainen Auni, Vänskä Matti, Lehtikangas Maija, Lakkisto Päivi, Hämäläinen Sari, Koivula Irma, Jantunen Esa, Pulkki Kari. 2015. Human plasma cell-free DNA as a predictor of infectious complications of neutropenic fever in hematological patients. Infectious Diseases 47 4: 255-259. 2015
• Valtola Jaakko, Varmavuo Ville, Ropponen Antti, Nihtinen Anne, Partanen Anu, Vasala Kaija, Lehtonen Päivi, Penttilä Karri, Pyörälä Marja, Kuittinen Taru, Silvennoinen Raija, Nousiainen Tapio, Pelkonen Jukka, Mäntymaa Pentti, Jantunen Esa. 2015. Blood graft cellular composition and posttransplant recovery in non-Hodgkin's lymphoma patients mobilized with or without plerixafor: A prospective comparison. Transfusion 55 10: 2358-2368. 2015
• Harjama Liisa, Kuitunen Hanne, Turpeenniemi-Hujanen Taina, Haapasaari Kirsi Maria, Leppä Sirpa, Mannisto Susanna, Karjalainen-Lindsberg Marja-Liisa, Lehtinen Tuula, Eray Mine, Vornanen Martine, Haapasalo Hannu, Soini Ylermi, Jantunen Esa, Nousiainen Tapio, Vasala Kaija, Kuittinen Outi. 2015. Constant pattern of relapse in primary central nervous lymphoma patients treated with high-dose methotrexate combinations. A Finnish retrospective study. ACTA ONCOLOGICA 54 6: 939-943. 2015
• Lemma Siria A, Pasanen Anna Kaisa, Haapasaari Kirsi-Maria, Sippola Antti, Sormunen Raija, Soini Ylermi, Jantunen Esa, Koivunen Petri, Salokorpi Niina, Bloigu Risto, Turpeenniemi-Hujanen Taina, Kuittinen Outi. 2015. Similar chemokine receptor profiles in lymphomas with central nervous system involvement - possible biomarkers for patient selection for central nervous system prophylaxis, a retrospective study. EUROPEAN JOURNAL OF HAEMATOLOGY [epub ahead of print 7 AUG 2015] -: -. 2015
• Kuusisto Milla Elvi Linnea, Haapasaari Kirsi-Maria, Turpeenniemi-Hujanen Taina, Jantunen Esa, Soini Ylermi, Peroja Pekka, Bloigu Risto, Karihtala Peeter, Kuittinen Outi. 2015. High intensity of cytoplasmic peroxiredoxin VI expression is associated with adverse outcome in diffuse large B-cell lymphoma independently of International Prognostic Index. JOURNAL OF CLINICAL PATHOLOGY 68: 552-556. 2015
• Jantunen E, Siitonen S, Karjalainen-Lindsberg M-L. 2014. Epäselvä kuumeilu, suurentunut plasman ferritiinipitoisuus ja nopeasti kehittynyt monielinvaurio. DUODECIM 130 3: 269-277. 2014
• Jantunen E, Varmavuo V. 2014. Plerixafor for mobilization of blood stem cells in autologous transplantation: an update. EXPERT OPINION ON BIOLOGICAL THERAPY 14 6: 851-861. 2014
• Kolstad Arne, Laurell Anna, Jerkeman Mats, Grønbæk Kirsten, Elonen Erkki, Räty Riikka, Pedersen Lone Bredo, Loft Annika, Bogsrud Trond Velde, Kimby Eva, Hansen Per Boye, Fagerli Unn-Merete, Nilsson-Ehle Herman, Lauritzsen Grete Fossum, Lehmann Anne Kristine, Sundstrom Christer, Karjalainen-Lindsberg Marja-Liisa, Ralfkiaer Elisabeth, Ehinger Mats, Delabie Jan et al (including Jantunen Esa). 2014. Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma. BLOOD 123 19: 2953-2959. 2014
• Pirnes-Karhu Sini, Jantunen Esa, Mäntymaa Pentti, Mustjoki Satu, Alhonen Leena, Uimari Anne. 2014. Spermidine/spermine N1-acetyltransferase activity associates with white blood cell count in myeloid leukemias. EXPERIMENTAL HEMATOLOGY 42 7: 574-580. 2014
• Pirnes-Karhu S, Mäntymaa P, Sironen R, Mäkinen PI, Wojciechowski S, Juutinen S, Koistinaho J, Hörkkö S, Jantunen E, Alhonen L, Uimari A. 2013. Enhanced polyamine catabolism disturbs hematopoietic lineage commitment and leads to a myeloproliferative disease in mice overexpressing spermidine/spermine N 1-acetyltransferase. AMINO ACIDS 2013 Jul 9. [Epub ahead of print]: -. 2013
• Vänskä M, Purhonen AK, Koivula I, Jantunen E, Hämäläinen S, Pulkki K, Juutilainen A.. 2013. Soluble form of urokinase-type plasminogen activator receptor as a diagnostic and prognostic marker in hematological patients with neutropenic fever. LEUKEMIA & LYMPHOMA 2013 Jul 22: 1-2. 2013
• Varmavuo V, Rimpiläinen J, Kuitunen H, Nihtinen A, Vasala K, Mikkola M, Kutila A, Lehtonen P, Kuittinen T, Mäntymaa P, Nousiainen T, Kuittinen O, Jantunen E. 2013. Engraftment and outcome after autologous stem cell transplantation in plerixafor-mobilized non-Hodgkin's lymphoma patients.. Transfusion e-pub: e-pub. 2013
• Varmavuo V, Rimpiläinen J, Kuitunen H, Nihtinen A, Vasala K, Mikkola M, Kutila A, Lehtonen P, Kuittinen T, Mäntymaa P, Nousiainen T, Kuittinen O, Jantunen E. 2013. Engraftment and outcome after autologous stem cell transplantation in plerixafor-mobilized non-Hodgkin's lymphoma patients. S420-S421. 2013
• Varmavuo V, Mäntymaa P, Silvennoinen R, Nousiainen T, Kuittinen T, Jantunen E. 2013. CD34+ cell subclasses and lymphocyte subsets in blood grafts collected after various mobilization methods in myeloma patients. Transfusion 53: 1024-1032. 2013
• Alhonen L, Pirnes-Karhu A, Uimari A, Jantunen E, Mäntymaa P, Määttä J, Finnilä M, Mustajoki S. 2013. New insight into mechanisms of myeloproliferative disorders, Main Symposia And Workshops. 575. 2013
• Pasanen AK, Haapasaari KM, Peltonen J, Soini Y, Jantunen E,. 2013. Cell cycle regulation score predicts relapse-free survival in non-germinal centre diffuse large B-cell lymphoma patients treated by means of immunochemotherapy. EUROPEAN JOURNAL OF HAEMATOLOGY 91: 29-36. 2013
• Jantunen E, Ropponen A, Siitonen T, Niittyvuopio R, Sankelo M, Putkonen M, Varmavuo V, Pyörälä M, Kuittinen T, Silvennoinen R, Kutila A, Nihtinen A, Vasala K, Lehtonen P, Sikiö A, Valonen P, Nousiainen T, Pelkonen J, Mäntymaa P. 2013. Graft and outcome in autologous stem cell transplantation: a prospective GOA study. S532. 2013
• Jantunen E, Pyörälä M, Kuittinen T, Mäntymaa P, Koljonen E, Kuittinen O, Kuitunen H, Nousiainen T. 2013. Is autologous stem cell transplantation feasible in solid organ transplant recipients with non-Hodgkin's lymphoma?. S422. 2013
• Jantunen E, Boumendil A, Finel H, Luan JJ, Johnson P, Rambaldi A, Haynes A, Duchosal MA, Bethge W, Biron P, Carlson K, Craddock C, Rudin C, Finke J, Salles G, Kroschinsky F, Sureda A, Dreger P on behalf of Lymphoma Working Party of the EBMT.. 2013. Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT. BLOOD 121: 2529-2532. 2013
• Lemma S, Karihtala P, Haapasaari KM, Jantunen E, Soini Y, Bloigu R, Pasanen AK, Turpeenniemi-Hujanen T, Kuittinen O.. 2013. Biological roles and prognostic values of the epithelial-mesenchymal transition-mediating transcription factors Twist, ZEB1 and Slug in diffuse large B-cell lymphoma. HISTOPATHOLOGY 62: 326-333. 2013
• Peroja P, Pasanen A K, Haapasaari K-M, Jantunen E, Soini Y, Turpeenniemi-Hujanen T, Bloigu R, Lilja L, Kuittinen O, Karihtala P. 2012. Oxidative stress and redox state-regulating enzymes have prognostic relevance in diffuse large B-cell lymphoma. Experimental Hematology & Oncology 1: 2. 2012
• Vänskä M, Koivula I, Jantunen E, Hämäläinen S, Purhonen AK, Pulkki K, Juutilainen A.. 2012. IL-10 combined with procalcitonin improves early prediction of complications of febrile neutropenia in hematological patients.. CYTOKINE 2012 Dec;60 3: 787-92. 2012
• Varmavuo V, Rimpiläinen J, Nihtinen A, Vasala K, Mikkola M, Lehtonen P, Kuittinen T, Mäntymää P, Nousiainen T, Kuittinen O, Jantunen E. 2012. Comparison of Post-Transplant Outcomes in Non-Hodgkin Lymphoma (NHL) Patients Mobilized with or without Plerixafor Added to Chemomobilization. BLOOD 120: Abstract 4520. 2012
• Varmavuo V, Mäntymaa P, Nousiainen T, Valonen P, Kuittinen T, Jantunen E, Valonen P. 2012. Blood graft composition after plerixafor injection in NHL patients EUROPEAN JOURNAL OF HAEMATOLOGY 89: 128-135. 2012
• Varmavuo V, Mäntymaa P, Kuittinen T, Nousiainen T, Jantunen E. 2012. Pre-emptive plerixafor injection increases blood neutrophil, lymphocyte and monocyte counts in addition to CD34+ counts in patients with non-Hodgkin lymphoma mobilizing poorly with chemotherapy plus G-CSF: potential implications for apheresis and graft composition. Transfusion and Apheresis Science 46: 257-262. 2012
• Sipola P, Vanninen E, Jantunen E, Nousiainen T, Kiviniemi M, Hartikainen J, Kuittinen T. 2012. A prospective comparison of cardiac magnetic resonance imaging and radionuclide ventriculography in the assessment of cardiac function in patients treated with anthracycline-based chemotherapy NUCLEAR MEDICINE COMMUNICATIONS 33 1: 51-59. 2012
• Räty R, Honkanen T, Jantunen E, Jyrkkiö S, Karjalainen-Lindsberg ML, Kuittinen O, Lehto M, Mikkola M, Poikonen E, Rauhala A, Rimpiläinen J, Räsänen A, Siitonen S, Suominen M, Vapaatalo M, Elonen E.. 2012. Prolonged immunochemotherapy with rituximab, cytarabine and fludarabine added to cyclophosphamide, doxorubicin, vincristine and prednisolone and followed by rituximab maintenance in untreated elderly patients with mantle cell lymphoma: a prospective study by the Finnish Lymphoma Group. LEUKEMIA & LYMPHOMA 53: 1920-1928. 2012
• Purhonen AK, Vänskä M, Hämäläinen S, Pulkki K, Lehtikangas M, Kuittinen T, Nousiainen T, Koivula I, Jantunen E, Juutilainen A. 2012. Plasma copeptin in the assessment of febrile neutropenia. PEPTIDES 36 1: 129-132. 2012
• Varmavuo V, Mäntymaa P, Kuittinen T, Nousiainen T, Jantunen E. 2012. Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin's lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony-stimulating factor Transfusion 52: 1785-1791. 2012
• Mounier N, Canals C, Gisselbrecht C, Cornelissen J, Foa R, Conde E, Maertens J, Attal M, Rambaldi A, Crawley C, Luan JJ, Brune M, Wittnebel S, Cook G, van Imhoff GW, Pfreundschuh M, Sureda A, for the Lymphoma Working Party of the European Blood and Marrow Transplantation Registry (EBMT). 2012. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 18 5: 788-793. 2012
• Jantunen E, Varmavuo V, Silvennoinen R, Valonen P, Kuittinen T, Nousiainen T, Mäntymaa P. 2012. Comparison of blood graft cellular content in myeloma (MM) patients and non-hodgkin lymphoma (NHL) patients mobilized with chemotherapy plus G-CSF with or without plerixafor. BLOOD 120: Abstract 4414. 2012
• Jantunen E, Varmavuo V, Juutilainen A, Kuittinen T, Mahlamäki E, Mäntymaa P, Nousiainen T. 2012. Kinetics of blood CD34+ cells after chemotherapy plus G-CSF in poor mobilizers: implications for pre-emptive plerixafor use. ANNALS OF HEMATOLOGY 91: 1073-1079. 2012
• Jantunen E, Sureda A. 2012. The evolving role of stem cell transplants in lymphomas. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 18 5: 660-673. 2012
• Jantunen E, Ruottinen S, Kuittinen T, Nousiainen T. 2012. Aikuisten immunologinen trombosytopenia - mitä uutta?. SUOMEN LÄÄKÄRILEHTI 67: 1416-1419. 2012
• Jantunen E, Lemoli RM. 2012. Preemptive use of plerixafor in difficult-to-mobilize patients: an emerging concept. Transfusion 52: 906-914. 2012
• Jantunen E, Canals C, Attal M, Thomson K, Milpied N, Buzyn A, Ferrant A, Biron P, Crawley C, Schattenberg A, Luan JJ, Tilly H, Rio B, Wijermans PW, Dreger P, Sureda A; Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (EBMT). 2012. Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT). ANNALS OF ONCOLOGY (DORDRECHT, ESMO) 23: 166-171. 2012
• Jantunen E, Canals C, Attal M, Thomson K, Milpied N, Buzyn A, Ferrant A, Biron P, Crawley C, Schattenberg A, Luan JJ, Tilly H, Rio B, Wijermans PW, Dreger P, Sureda A, Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (EBMT).. 2012. Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT). ANNALS OF ONCOLOGY (DORDRECHT, ESMO) 23: 166-171. 2012
• d'Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, Holte H, Osterborg A, Merup M, Brown P, Kuittinen O, Erlanson M, Ostenstad B, Fagerli UM, Gadeberg OV, Sundström C, Delabie J, Ralfkiaer E, Vornanen M, Toldbod HE. 2012. Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01. JOURNAL OF CLINICAL ONCOLOGY 30 25: 3093-3099. 2012
• Magga J, Savchenko E, Malm T, Rolova T, Pollari E, Valonen P, Lehtonen S, Jantunen E, Aarnio J, Lehenkari P, Koistinaho M, Muona A, Koistinaho J. 2012. Production of monocytic cells from bone marrow stem cells: therapeutic usage in Alzheimer's disease. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE 2012 May;16(5): 1060-73. 2012
• Juutilainen A, Hämäläinen S, Pulkki K, Kuittinen T, Nousiainen T, Jantunen E, Koivula I. 2011. Biomarkers for bacteremia and severe sepsis in hematological patients with neutropenic fever: multivariate logistic regression analysis and factor analysis LEUKEMIA & LYMPHOMA 52 12: 2349-2355. 2011
• Vänskä Matti, Koivula Irma, Hämäläinen Sari, Pulkki Kari, Nousiainen Tapio, Jantunen Esa, Juutilainen Auni. 2011. High pentraxin 3 level predicts septic shock and bacteremia at the onset of febrile neutropenia after intensive chemotherapy of hematologic patients HAEMATOLOGICA 96 9: 1385-1389. 2011
• Koivula I, Hämäläinen S, Jantunen E, Pulkki K, Kuittinen T, Nousiainen T, Juutilainen A. 2011. Elevated procalcitonin predicts Gram-negative sepsis in haematological patients with febrile neutropenia SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES 43 6-7: 471-478. 2011
• Juutilainen A, Vänskä M, Pulkki K, Hämäläinen S, Nousiainen T, Jantunen E, Koivula I. 2011. Pentraxin 3 predicts complicated course of febrile neutropenia in haematological patients, but the decision level depends on the underlying malignancy EUROPEAN JOURNAL OF HAEMATOLOGY 87: 441-447. 2011
• Jantunen E, Penttilä K, Pyörälä M, Mahlamäki E, Kuittinen T, Nousiainen T. 2011. Addition of plerixafor to a chemotherapy plus G-CSF mobilization in hard-to-mobilize patients. BONE MARROW TRANSPLANTATION 46: 308-309. 2011
• Juutilainen A, Hämäläinen S, Niemenpää J, Kuittinen T, Pulkki K, Koivula I, Niskanen L, Jantunen E. 2011. Serum cortisol and inflammatory response in neutropenic fever ANNALS OF HEMATOLOGY 90: 1467-1475. 2011
• Jantunen Esa. 2011. Novel strategies for blood stem cell mobilization: special focus on plerixafor EXPERT OPINION ON BIOLOGICAL THERAPY 11 9: 1241-1248. 2011
• Jantunen E. 2011. Novel blood stem cell mobilization strategies: special focus on plerixafor EXPERT OPINION ON BIOLOGICAL THERAPY 11: 1241-1248. 2011
• Jantunen E, Kuittinen T, Mahlamäki E, Pyörälä M, Mäntymaa P, Nousiainen T. 2011. Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience EUROPEAN JOURNAL OF HAEMATOLOGY 86 4: 299-304. 2011
• Jantunen E, Fruehauf S. 2011. Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens. BONE MARROW TRANSPLANTATION 46 5: 627-635. 2011
• Taskinen Minna, Jantunen Esa, Kosma Veli-Matti, Bono Petri, Karjalainen-Lindsberg Marja-Liisa, Leppä Sirpa. 2010. Prognostic impact of CD31-positive microvessel density in follicular lymphoma patients treated with immunochemotherapy. EUROPEAN JOURNAL OF CANCER 46 13: 2506-2512. 2010
• Syrjälä H, Ohtonen P, Kinnunen U, Räty R, Elonen E, Nousiainen T, Jantunen E, Remes K, Itälä-Remes M, Silvennoinen R, Koistinen P, Finnish Leukemia Group. 2010. Blood stream infections during chemotherapy-induced neutropenia in adult patients with acute myeloid leukemia: treatment cycle matters. JOURNAL OF INFECTIOUS DISEASES 29: 1211-1218. 2010
• Matinlauri I, Juutilainen A, Hämäläinen S, Koivula I, Kuittinen T, Jantunen E. 2010. Fibrinogen and antithrombin in hematological patients with neutropenic fever. CENTRAL EUROPEAN JOURNAL OF MEDICINE 5 4: 520-526. 2010
• Matinlauri I, Juutilainen A, Hämäläinen S, Koivula I, Kuittinen T, Jantunen E. 2010. Plasma fibrinogen and antithrombin in haematological patients with neutropenic fever. CENTRAL EUROPEAN JOURNAL OF MEDICINE 5: 520-526. 2010
• Jantunen E, Kvalheim G. 2010. Mobilization strategies in hard-to-mobilize patients with lymphoid malignancies. EUROPEAN JOURNAL OF HAEMATOLOGY 85: 463-471. 2010
• Kuittinen T, Jantunen E, Vanninen E, Mussalo H, Nousiainen T, Hartikainen J. 2010. Late potentials and QT dispersion after high-dose chemotherapy in patients with non-Hodgkin lymphoma. CLINICAL PHYSIOLOGY AND FUNCTIONAL IMAGING 30: 175-180. 2010
• Jantunen E. 2010. Myeloomapotilaiden uudet lääkkeet SUOMEN LÄÄKÄRILEHTI 65: 3971-3976. 2010
• Jantunen E, Jyrkkiö S, Kuittinen T, Lehtinen T, Janes R, Elonen E, Volin L. 2010. Lymfoomapotilaiden allogeeniset kantasolujen sirrot DUODECIM 126: 167-173. 2010
• Hämäläinen S, Juutilainen A, Kuittinen T, Nousiainen T, Matinlauri I, Pulkki K, Koivula I, Jantunen E. 2010. Serum amino-terminal pro-brain natriuretic peptide in hematological patients with neutropenic fever: a prospective comparison with C-reactive protein. LEUKEMIA & LYMPHOMA 51 6: 1040-1046. 2010
• Juutilainen A, Hämäläinen A, Matinlauri I, Kuittinen T, Nousiainen T, Pulkki K, Koivula I, Jantunen E. 2010. Serial plasma lactate measurements in haematological patients with neutropenic fever. SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES 42: 102-108. 2010
• Hämäläinen S, Juutilainen A, Matinlauri I, Kuittinen T, Ruokonen E, Koivula I, Jantunen E. 2009. Serum vascular endothelial growth factor in adult haematological patients with neutropenic fever: a comparison with C-reactive protein. EUROPEAN JOURNAL OF HAEMATOLOGY 83: 251-257. 2009
• Hämäläinen S, Kuittinen T, Matinlauri I, Nousiainen T, Koivula I, Jantunen E. 2009. Severe sepsis in autologous stem cell transplant recipients: Microbiological aetiology, risk factors and outcome. SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES 41 1: 14-20. 2009
• Jantunen E. 2008. Aikuispotilaiden autologiset kantasolusiirrot. SUOMEN LÄÄKÄRILEHTI 63 12-13: 1171-1177. 2008
• Usvasalo A, Räty R, Knuutila S, Vettenranta K, Harila-Saari A, Jantunen E, Kauppila M, Koistinen P, Parto K, Riikonen P, Salmi TT, Silvennoinen R, Elonen E, Saarinen-Pihkala UM. 2008. Acute lymphoblastic leukemia in adolescents and young adults in Finland. HAEMATOLOGICA 93: 1161-1168. 2008
• Nyman H, Jantunen E, Juvonen E, Elonen E, Böhm J, Kosma V-M, Enblad G, Karjalainen-Lindsberg M-L, Leppä S. 2008. Impact of germinal center and non-germinal center phenotypes on overall and failure-free survival after high-dose chemotherapy and auto-SCT in primary diffuse large B-cell lymphoma. BONE MARROW TRANSPLANTATION 42: 93-98. 2008
• Leppä S, Elonen E, Jantunen E, Jyrkkiö S, Karjalainen-Lindsberg M-L, Kuittinen O, Vasala K, Lehtinen T. 2008. Diffuusin suurisoluisen B-solulymfooman hoito SUOMEN LÄÄKÄRILEHTI 63 4: 7-15. 2008
• Jantunen E. 2008. Myelooman muuttuva hoito DUODECIM 124: 59-66. 2008
• Jantunen E, Kuittinen T, Elonen E. 2008. Iäkkäiden potilaiden pahanlaatuisten veritautien hoito. DUODECIM 124: 2181-2188. 2008
• Jantunen E, Nihtinen A, Anttila V-J. 2008. Changing landscape of invasive aspergillosis in allogeneic stem cell transplant recipients. TRANSPLANT INFECTIOUS DISEASE: AN OFFICIAL JOURNAL OF THE TRANSPLANTATION SOCIETY 10: 156-161. 2008
• Jantunen E, Kuittinen T. 2008. Blood stem cell mobilization and collection in patients with lymphoproliferative diseases: practical issues EUROPEAN JOURNAL OF HAEMATOLOGY 80: 287-295. 2008
• Jantunen E, Itälä M, Siitonen T, Kuittinen T, Heiskanen J, Koivunen E, Juvonen E, Silvennoinen R, Nousiainen T, Koistinen P, Volin L, Remes K. 2008. Blood stem cell mobilization and collection in patients with chronic lymphocytic leukaemia: a nationwide analysis BONE MARROW TRANSPLANTATION 41: 239-244. 2008
• Jantunen E, Canals C, Rambaldi A, Ossenkoppele G, Allione B, Blaise D, Conde E, Tilly H, Cook G, Clark F, Gallamini A, Haynes A, Mounier N, Dreger P, Pfreundschuh M, Sureda A, the EBMT Lymphoma Working Party. 2008. Autologous stem cell transplantation in elderly patients (> or =60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry HAEMATOLOGICA 93: 1837-1842. 2008
• Hämäläinen S, Kuittinen T, Matinlauri I, Nousiainen T, Koivula I, Jantunen E. 2008. Neutropenic fever and severe sepsis in adult acute myeloid leukemia (AML) patients receiving intensive chemotherapy: causes and consequences. LEUKEMIA & LYMPHOMA 49: 495-501. 2008
• Jyrkkiö S, Jantunen E, Keskinen L, Kuittinen O, Leppä S, Vasala K, Vornanen M, Lehtinen T. 2007. Follikulaarisen lymfooman hoito. SUOMEN LÄÄKÄRILEHTI 62: 1729-1733. 2007
• Koistinen P, Räty R, Itälä M, Jantunen E, Koivunen E, Nousiainen T, Pelliniemi T-T, Remes K, Ruutu T, Savolainen E-R, Siitonen T, Silvennoinen R, Volin L, Elonen E, for the Finnish Leukaemia Group. 2007. Long-term outcome of intensive chemotherapy for adults with de novo acute myeloid leukaemia (AML): the nationwide AML-92 study by the Finnish Leukaemia Group. EUROPEAN JOURNAL OF HAEMATOLOGY 78: 477-486. 2007
• Jantunen E, Heinonen K, Mahlamäki E, Penttilä K, Kuittinen T, Lehtonen P, Pyörälä M, Hänninen A, Nousiainen T. 2007. Secondary acute promyelocytic leukemia: An increasingly common entity. LEUKEMIA & LYMPHOMA 48 1: 190-191. 2007
• Daikeler T, Kötter I, Bocelli Tyndall C, Apperley J, Attarbaschi A, Guardiola P, Gratwohl A, Jantunen E, Marmont A, Porretto F, Musso M, Maurer B, Rinaldi N, Saccardi R, Tyndall A, for the EBMT Autoimmune Diseases Working Party,. 2007. Haematopoietic stem cell transplantation for vasculitis including Behcet's disease and polychondritis: a retrospective analysis of patients recorded in the European Bone Marrow Transplantation and European League Against Rheumatism databases and a. ANNALS OF THE RHEUMATIC DISEASES 66: 202-207. 2007
• Jantunen E, Kataja V. 2007. Mukosiitti - syövän hoidon merkittävä pulma. SUOMEN LÄÄKÄRILEHTI 62 12: 1243-1247. 2007
• Jantunen E, Itälä M, Lehtinen T, Kuittinen O, Koivunen E, Leppä S, Juvonen E, Koistinen P, Wiklund T, Nousiainen T, Remes K, Volin L. 2006. Early treatment-related mortality in adult autologous stem cell transplant recipients: a nation-wide survey of 1482 transplanted patients EUROPEAN JOURNAL OF HAEMATOLOGY 76: 245-250. 2006
• Jantunen E, Itälä M, Siitonen T, Juvonen E, Koivunen E, Koistinen P, Volin L, Remes K, Nousiainen T. 2006. Autologous stem cell transplantation in patients with chronic lymphocytic leukaemia: the Finnish experience. BONE MARROW TRANSPLANTATION 37: 1093-1098. 2006
• Jantunen E, Kuittinen T, Penttilä K, Lehtonen P, Mahlamäki E, Nousiainen T. 2006. High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (>or=65 years) myeloma patients: comparison with younger patients on the same protocol. BONE MARROW TRANSPLANTATION 37: 917-922. 2006
• Jantunen E, Penttilä K, Kuittinen T, Nousiainen T. 2006. Anagrelidi krooniseen myeloproliferatiiviseen tautiin liittyvän trombosytoosin hoidossa. DUODECIM 122: 453-457. 2006
• Jantunen E. 2006. Autologous stem cell transplantation beyond 60 years of age. BONE MARROW TRANSPLANTATION 38: 715-720. 2006
• Kuittinen T, Jantunen E, Vanninen E, Mussalo H, Vuolteenaho O, Ala-Kopsala M, Nousiainen T, Hartikainen J. 2006. Cardiac effects within 3 months of BEAC high-dose therapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation EUROPEAN JOURNAL OF HAEMATOLOGY 77: 120-127. 2006
• Kuittinen T, Husso-Saastamoinen M, Sipola P, Vuolteenaho O, Ala-Kopsala M, Nousiainen T, Jantunen E, Hartikainen J. 2005. Very acute cardiac toxicity during BEAC chemotherapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation BONE MARROW TRANSPLANTATION 36: 1077-1082. 2005
• Kuittinen T, Wiklund T, Remes K, Elonen E, Lehtinen T, Kuittinen O, Leppä S, Putkonen M, Räty R, Turpeenniemi-Hujanen T, Nousiainen T, Jantunen E. 2005. Outcome of progressive disease after autologous stem cell transplantation in patients with non-Hodgkin's lymphoma: a nation-wide survey EUROPEAN JOURNAL OF HAEMATOLOGY 75: 199-205. 2005
• Jantunen E, Koivunen E, Putkonen M, Siitonen T, Juvonen E, Nousiainen T. 2005. Autologous stem cell transplantation in patients with high-risk plasmacytoma. EUROPEAN JOURNAL OF HAEMATOLOGY 74: 402-406. 2005
• Jantunen E, Vornanen M. 2005. Perifeeriset T-solulymfoomat. DUODECIM 60 37: 3611-3617. 2005
• Jantunen E, Luosujärvi R. 2005. Stem cell transplantation in autoimmune diseases: an uptake. Annals of Medicine 37: 533-541. 2005
• Vornanen M, Heikkinen M, Jantunen E. 2004. Maha-suolikanavan lymfoomat. DUODECIM 120: 1859-1865. 2004
• Snowden JA, Passweg J, Moore JJ, Milliken S, Cannell P, Van Laar JM, Verburg R, Szer J, Taylor K, Joske D, Rule S, Bingham SJ, Emery P, Burt RK, Lowenthal RM, Durez P, McKendry RJ, Pavletic SZ, Espigado I, Jantunen E, Kashyap A, Rabusin M, Brooks P, Bredeson C, Tyndall A. 2004. Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR JOURNAL OF RHEUMATOLOGY 31: 482-488. 2004
• Jantunen E, Wiklund T, Juvonen E, Putkonen M, Lehtinen T, Kuittinen O, Franssila K, Söderström K-O, Leppä S, Elonen E, Remes K, Nousiainen T. 2004. Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey. BONE MARROW TRANSPLANTATION 33 4: 405-410. 2004
• Kuittinen T, Nousiainen T, Halonen P, Mahlamäki E, Jantunen E. 2004. Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma BONE MARROW TRANSPLANTATION 33: 907-912. 2004
• Ruutu T, Koivunen E, Nousiainen T, Pelliniemi T-T, Almqvist A, Anttila P, Jantunen E, Koistinen P, Koponen A, Mikkola M, Oksanen K, Pulli T, Remes K, Sarkkinen R, Silvennoinen R, Timonen T, Vanhatalo S, Elonen E, for the Finnish Leukaemia Group. 2004. Oral treatment of acute myeloid leukaemia with etoposide, thioguanine, and idarubicin (ETI) in elderly patients: a prospective randomised comparison with intravenous cytarabine, idarubicin, and thioguanine in the second and third treatment cycle. EUROPEAN JOURNAL OF HAEMATOLOGY 72: 38-44. 2004
• Jantunen E, Siitonen T, Putkonen M, Koivunen E, Juvonen E, Nousiainen T, Koistinen P. 2004. Autologous stem cell transplantation in patients with primary amyloidosis: a nation-wide survey. LEUKEMIA & LYMPHOMA 45: 2485-2489. 2004
• Jantunen E, Nihtinen A, Volin L, Juvonen E, Parkkali T, Ruutu T, Anttila V-J. 2004. Candidaemia in allogeneic stem cell transplant recipients: low risk without fluconazole prophylaxis BONE MARROW TRANSPLANTATION 34: 891-895. 2004
• Jantunen E, Kettunen J, Niemitukia L, Ropponen K, Vornanen M, Voutilainen L, Mussalo H, Nousiainen T. 2004. Primaarit luulymfoomat. KYS:n kokemukset 1990-2003 DUODECIM 120: 2681-2687. 2004
• Jantunen E, D¿Amore F. 2004. Stem cell transplantation for peripheral T-cell lymphomas. LEUKEMIA & LYMPHOMA 45: 441-446. 2004
• Jantunen E, Salonen J, Juvonen E, Koivunen E, Siitonen T, Lehtinen T, Kuittinen O, Leppä S, Anttila V-J, Itälä M, Wiklund T, Remes K, Nousiainen T. 2004. Invasive fungal infections in autologous stem cell transplant recipients: a nation-wide study of 1188 transplanted patients. EUROPEAN JOURNAL OF HAEMATOLOGY 73: 174-178. 2004
• Jantunen E, Mahlamäki E, Heinonen K, Nousiainen T. 2003. Multiple complete remissions in a patient with acute myeloid leukemia (M4eo) with low-dose cytosine arabinoside and all-trans retinoic acid LEUKEMIA & LYMPHOMA 44 5: 883-885. 2003
• Jantunen E, Putkonen M, Nousiainen T, Pelliniemi T-T, Mahlamäki E, Remes K. 2003. Low-dose or intermediate-dose cyclophoshamide plus granulocyte colony-stimulating factor for progenitor cell mobilisation in patients with multiple myeloma. BONE MARROW TRANSPLANTATION 31: 347-351. 2003
• Jantunen E, Volin L, Salonen O, Piilonen A, Parkkali T, Anttila V-J, Paetau A, Ruutu T. 2003. Central nervous system aspergillosis in allogeneic stem cell transplant resipients BONE MARROW TRANSPLANTATION 31: 191-196. 2003
• Jantunen E, Kuittinen T, Nousiainen T. 2003. Is chemotherapy scoring useful to predict progenitor cell mobilisation in patient with non-Hodgkin`s lymphoma? BONE MARROW TRANSPLANTATION 32: 569-573. 2003
• Jantunen E, Kuittinen T, Nousiainen T. 2003. BEAC or BEAM for high-dose therapy in patients with non-Hodgkin's lymphoma? A single centre analysis on toxicity and efficacy. LEUKEMIA & LYMPHOMA 44: 1151-1158. 2003
• Jantunen E, Juvonen E, Wiklund M, Putkonen M, Nousiainen T. 2003. High-dose therapy supported by autologous stem cell transplantation in patients with enteropathy-associated T-cell lymphoma. LEUKEMIA & LYMPHOMA 44 12: 2163-2164. 2003
• Jantunen E, Anttila V-J, Ruutu T. 2002. Aspergillus infections in allogeneic stem cell transplant recipients: have we made any progress?. BONE MARROW TRANSPLANTATION 30: 925-929. 2002
• Jantunen E, Kuittinen T, Nousiainen T. 2002. A pilot study on feasibility and efficacy of amifostine preceding high-dose melphalan with autologous stem cell support in myeoloma patients. LEUKEMIA & LYMPHOMA 43: 1961-1965. 2002
• Jantunen E, Mahlamäki E, Hämäläinen E, Heinonen K, Nousiainen T. 2002. Suurten granulaisten lymfosyyttien leukemia. DUODECIM 118: 177-181. 2002
• Jantunen E, Piilonen A, Volin L, Ruutu P, Parkkali T, Koukila-Kähkölä P, Ruutu T. 2002. Radiologically guided fine needle lung biopsies in the evaluation of focal pulmonary lesions in allogeneic stem cell transplant recipients. BONE MARROW TRANSPLANTATION 29: 353-356. 2002
• Jantunen E. 2002. Bisphosphonate therapy in multiple myeloma: past, present, future. EUROPEAN JOURNAL OF HAEMATOLOGY 69: 257-264. 2002
• Nousiainen T, Jantunen E, Vanninen E, Hartikainen J. 2002. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. BRITISH JOURNAL OF CANCER 86: 1697-1700. 2002
• Nousiainen T, Vanninen E, Jantunen E, Puustinen J, Remes J, Rantala A, Hartikainen J. 2002. Concomitant impairment of left ventricular systolic and diastolic function during doxorubicin therapy: A prospective radionuclide ventriculographic and echocardiographic study. LEUKEMIA & LYMPHOMA 43 9: 1807-1811. 2002
• Nousiainen T, Vanninen E, Jantunen E, Puustinen J, Remes J, Rantala A, Vuolteenaho O, Hartikainen J. 2002. Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction. JOURNAL OF INTERNAL MEDICINE 251: 228-234. 2002
• Oinonen R, Jantunen E, Itälä M, Lehtinen T, Kuittinen O, Franssila K, Wiklund T, Elonen E. 2002. Autologous stem cell transplantation in patients with mantle cell lymphoma. LEUKEMIA & LYMPHOMA 43: 1229-1237. 2002
• Nousiainen T, Vanninen E, Jantunen E, Remes J, Ritanen E, Vuolteenaho O, Hartikainen J. 2001. Neuroendocrine changes during the evolution of doxorubicin-induced left ventricular dysfunction in adult lymphoma patients. CLINICAL SCIENCE (LONDON) 101: 601-607. 2001
• Nousiainen T, Vanninen E, Jantunen E, Remes J, Kuikka J, Hartikainen J. 2001. Anthracycline-induced cardiomyopathy: long-term effects on myocardial cell integrity, cardiac adrenergic innervation and fatty acid uptake. CLINICAL PHYSIOLOGY AND FUNCTIONAL IMAGING 21 1: 123-128. 2001
• Nousiainen T, Vanninen E, Jantunen E, Puustinen J, Remes J, Rantala A, Hartikainen J. 2001. Comparison of echocardiography and radionuclide ventriculography in the follow-up of left ventricular systolic function in adult lymphoma patients during doxorubicin therapy JOURNAL OF INTERNAL MEDICINE 249: 297-303. 2001
• Kauppinen J, Nousiainen T, Jantunen E, Mattila R, Katila M-L. 1999. Hospital water supply as a source of disseminated Mycobacterium fortuitum infection in a leukemia patient. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY 20 5: 343-345. 1999
• Nousiainen T, Jantunen E, Vanninen E, Remes J, Vuolteenaho O, Hartikainen J. 1999. Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma EUROPEAN JOURNAL OF HAEMATOLOGY 62: 135-141. 1999
• Nousiainen T, Vanninen E, Rantala A, Jantunen E, Hartikainen J. 1999. QT dispersion and late potentials during doxorubicin therapy for non-Hodgkin's lymphoma. JOURNAL OF INTERNAL MEDICINE 245: 359-364. 1999
• Jantunen E, Myllykangas-Luosujärvi R. 1998. Kantasolujen siirrot reumataudeissa DUODECIM 114: 401-403. 1998
• Jantunen E, Nousiainen T. 1998. Interferonit veritautien hoidossa. DUODECIM 114: 1240-1247. 1998
• Nousiainen T, Jantunen E, Vanninen E, Remes J, Puustinen J, Rantala A, Vuolteenaho O, Hartikainen J. 1998. Acute neurohumoral and cardiovascular effects of idarubicin in leukemia patients. EUROPEAN JOURNAL OF HAEMATOLOGY 61: 347-353. 1998
• Purokivi M, Myllykangas-Luosujärvi R, Jantunen E. 1998. Reumapotilaiden metotreksaattihoidon vakavat haittavaikutukset. DUODECIM 114: 2187-2190. 1998
• Jantunen E, Paakkunainen P, Nousiainen T, Riikonen P, Voutilainen L, Mahlamäki E. 1997. Alkuvaiheen kokemuksia veren kantasolujen siirroista KYS:ssa. SUOMEN LÄÄKÄRILEHTI 52 3: 205-207. 1997
• Jantunen E, Ruutu P, Niskanen L, Volin L, Parkkali T, Koukila-Kähkölä P, Ruutu T. 1997. Incidence and risk factors for invasive fungal infektions in allogeneic BMT recipients. BONE MARROW TRANSPLANTATION 19: 801-808. 1997
• Kaipiainen-Seppänen O, Jantunen E, Kuusisto J, Marin S. 1996. Retroperitoneal fibrosis with antineutrophil cytoplasmic antibodies. JOURNAL OF RHEUMATOLOGY 23: 779-781. 1996
• Nieminen U, Jantunen E. 1996. Trombosytopeniat: Ruutu T, Rajamäki A, Krusius T, Veritaudit.Duodecim. 422-432. 1996
• Laakso M, Jantunen E. 1996. Bisphosphonate therapy in multiple myeloma ACTA ONCOLOGICA 35: 55-56. 1996
• Jantunen E, Kolho E, Ruutu P, Koukila-Kähkölä P, Virolainen M, Juvonen E, Volin L. 1996. Invasive cutaneous mucormycosis caused by Absidia corymbifera after allogeneic bone marrow transplantation after allogeneic bone marrow transplantation. BONE MARROW TRANSPLANTATION 18: 229-230. 1996
• Jantunen E, Remes J, Vanninen E, Riikonen P, Nousiainen T. 1996. Antrasykliinihoidon sydänhaitat. DUODECIM 112: 1274-1280. 1996
• Jantunen E, Nousiainen T. 1996. Pulsed dexamethasone for refractory idiopathic thrombocytopenic purpura. AMERICAN JOURNAL OF HEMATOLOGY 53 4: 281-282. 1996
• Jantunen E, Niskanen L. 1996. Bisfosfonaattien kliininen käyttö. SUOMEN LÄÄKÄRILEHTI 51 25: 2449-2454. 1996
• Jantunen E, Laakso M. 1996. Bisphosphonates in multiple myeloma: current status: future perspectives. BRITISH JOURNAL OF HAEMATOLOGY 93: 501-506. 1996
• Jantunen E, Lahtinen R, Laakso M. 1995. Klodronaatti ja myelooma DUODECIM 111: 1085-1087. 1995
• Jantunen E, Lahtinen R, Laakso M. 1995. Use of clodronate in multiple myeloma. LEUKEMIA & LYMPHOMA 19: 207-211. 1995
• Jantunen E, Vornanen M, Nousiainen T, Riikonen P. 1995. Burkittin leukemia-lymfooma DUODECIM 111: 2115-2121. 1995
• Kekomäki R, Jantunen E. 1995. Von Willebrandin tauti ja trombopatiat: Leikola J, Myllylä G, Verensiirrot.Duodecim. 287-295. 1995